Regional Differences in the Response to Acute Blood Pressure Lowering After Cerebral Hemorrhage

Kazunori Toyoda, MD, PhD, Yuko Y. Palesch, PhD, Masatoshi Koga, MD, PhD, Lydia Foster, MS, Haruko Yamamoto, MD, PhD, Sohei Yoshimura, MD, PhD, Masafumi Ihara, MD, PhD, Mayumi Fukuda-Doi, MD, PhD, Shuhei Okazaki, MD, PhD, Kanta Tanaka, MD, Kaori Miwa, MD, PhD, Yasuhiro Hasegawa, MD, PhD, Yoshiaki Shiokawa, MD, PhD, Toru Iwama, MD, PhD, Kenji Kamiyama, MD, PhD, Haruhiko Hoshino, MD, PhD, Thorsten Steiner, MD, PhD, Byung-Woo Yoon, MD, PhD, Yongjun Wang, MD, PhD, Chung Y. Hsu, MD, PhD, and Adnan I. Qureshi, MD, PhD, for the ATACH-2 Trial Investigators

Correspondence

Dr. Toyoda
toyoda@ncvc.go.jp

Neurology® 2021;96:e740-e751. doi:10.1212/WNL.00000000000011229

Abstract

Objective

To compare the impact of intensive blood pressure (BP) lowering right after intracerebral hemorrhage (ICH) on clinical and hematoma outcomes among patients from different geographic locations, we performed a prespecified subanalysis of a randomized, multinational, 2-group, open-label trial to determine the efficacy of rapidly lowering BP in hyperacute ICH (Antihypertensive Treatment of Acute Cerebral Hemorrhage [ATACH]-2), involving 537 patients from East Asia and 463 recruited outside of Asia.

Methods

Eligible patients were randomly assigned to a systolic BP target of 110 to 139 mm Hg (intensive treatment) or 140 to 179 mm Hg (standard treatment). Predefined outcomes were poor functional outcome (modified Rankin Scale score 4–6 at 90 days), death within 90 days, hematoma expansion at 24 hours, and cardiorenal adverse events within 7 days.

Results

Poor functional outcomes (32.0% vs 45.9%), death (1.9% vs 13.3%), and cardiorenal adverse events (3.9% vs 11.2%) occurred significantly less frequently in patients from Asia than those outside of Asia. The treatment-by-cohort interaction was not significant for any outcomes. Only patients from Asia showed a lower incidence of hematoma expansion with intensive treatment (adjusted relative risk [RR] 0.56, 95% confidence interval [CI] 0.38–0.83). Both Asian (RR 3.53, 95% CI 1.28–9.64) and non-Asian (RR 1.71, 95% CI 1.00–2.93) cohorts showed a higher incidence of cardiorenal adverse events with intensive treatment.

Conclusions

Poor functional outcomes and death 90 days after ICH were less common in patients from East Asia than those outside of Asia. Hematoma expansion, a potential predictor for poor clinical outcome, was attenuated by intensive BP lowering only in the Asian cohort.

ClinicalTrials.gov Identifier

NCT01176565.

Classification of Evidence

This study provides Class II evidence that, for patients from East Asia with ICH, intensive blood pressure lowering significantly reduces the risk of hematoma expansion.

MORE ONLINE

→ Class of Evidence

Criteria for rating therapeutic and diagnostic studies

[NPublic.org/coe](https://npublic.org/coe)

From the Department of Cerebrovascular Medicine (K. Toyoda, M.K., S.Y., K. Tanaka, K.M.), Center for Advancing Clinical and Translational Sciences (H.Y., M.F.-D., S.O.), and Department of Neurology (M.I.), National Cerebral and Cardiovascular Center, Suita, Japan; Department of Public Health Sciences (Y.Y.P., L.F.), Medical University of South Carolina, Charleston; Department of Neurology (Y.H.), St. Marianna University School of Medicine, Kawasaki; Department of Neurosurgery and Stroke Center (Y.S.), Kyorin University School of Medicine, Mitaka; Department of Neurosurgery (T.I.), Gifu University Graduate School of Medicine; Department of Neurosurgery (K.K.), Nakamura Memorial Hospital, Sapporo; Department of Neurology (H.H.), Tokyo Saiseikai Central Hospital, Japan; Department of Neurology (T.S.), Klinikum Frankfurt Höchst, Germany; Department of Neurology (B.-W.Y.), Seoul National University Hospital, South Korea; Beijing Tiantan Hospital (Y.W.), China; China Medical University (C.Y.H.), Taichung, Taiwan; and Zeenat Qureshi Stroke Research Center (A.I.Q.), University of Minnesota, Minneapolis.

Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Coinvestigators are listed in Appendix 2.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Glossary

ATACH = Antihypertensive Treatment of Acute Cerebral Hemorrhage; **BP** = blood pressure; **CI** = confidence interval; **ICH** = intracerebral hemorrhage; **INTERACT2** = Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial; **mRS** = modified Rankin Scale; **NIHSS** = NIH Stroke Scale; **RR** = relative risk; **SAMURAI** = Stroke Acute Management With Urgent Risk-Factor Assessment and Improvement; **SBP** = systolic BP.

Stroke was estimated to occur in ≈ 14 million population annually and was the second largest cause of death (≈ 5.5 million) and the second most common cause of disability-adjusted life-years (≈ 116 million) globally from 1990 through 2016.¹ Of all strokes, 14% to 18.5% were reportedly intracerebral hemorrhages (ICHs).^{2,3} Although both the incidence and mortality of ICH decreased in the past 2 decades worldwide, ICH is still a devastating disease.¹

Acute therapeutic strategies for ICH lag far behind those for acute ischemic stroke in their practical impact^{4,5}; among these, acute lowering of elevated blood pressure (BP) may attenuate early hematoma expansion and have the potential to decrease death and disability. The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT2) demonstrated possibly better functional outcomes for patients with acute ICH with early intensive lowering to a targeted systolic BP (SBP) of <140 mm Hg than the standard target of SBP <180 mm Hg (odds ratio 0.87, 95% confidence interval [CI] 0.75–1.01).⁶ However, another global randomized controlled trial, the Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH)-2 trial, which overlapped in time with INTERACT2, did not show benefit in reducing the rate of the primary outcome of death or disability, defined as a modified Rankin Scale (mRS) score of 4 to 6, between the 2 treatment groups with the same target level of SBP as in INTERACT2 (relative risk [RR] with intensive treatment 1.04, 95% CI 0.85–1.27).⁷ We hypothesized that the prevalence and geographic variety of patients from Asia would have affected the difference in the efficacy outcomes between the trials.

Methods

Classification of Evidence

The primary research question was to evaluate the geographic differences in clinical outcomes and early hematoma expansion after ICH between patients from East Asia and those outside of Asia. This study provides Class II evidence that, for patients from East Asia with ICH, intensive BP lowering significantly reduces the risk of hematoma expansion.

Standard Protocol Approvals, Registrations, and Patient Consents

ATACH-2 was registered in ClinicalTrials.gov (NCT01176565) and the University Hospital Medical Information Network clinical trial registry in Japan (UMIN 000006526) and was approved by ethics committees/competent authorities in all participating

sites. Informed consent was obtained from each participant, her/his legally authorized representative, or a relative.

Patients

ATACH-2 was a randomized, multinational, 2-group, open-label trial to determine the efficacy of rapidly lowering SBP in patients with hyperacute spontaneous supratentorial ICH from 110 sites in the United States, Japan, China, Taiwan, Germany, and South Korea.^{7–9} A detailed description of the protocol has been provided elsewhere.¹⁰ Briefly, patients with a Glasgow Coma Scale score ≥ 5 and an SBP ≥ 180 mm Hg on arrival at the emergency department and intraparenchymal hematoma with a volume <60 cm³ on initial non-contrast-enhanced CT were centrally randomized to undergo either intensive SBP lowering (target SBP 110–139 mm Hg) or standard SBP lowering (target SBP 140–179 mm Hg) in a 1:1 ratio within 4.5 hours of symptom onset.

IV nicardipine infusion was started to reduce hourly minimum SBP to the target level within 2 hours of randomization and to maintain this level through 24 hours for each participant. SBP was measured every 5 minutes for the first 15 minutes after initiation of nicardipine infusion followed by at least every 15 minutes for the remainder of the first hour and at least every 30 minutes during the period from 1 to 24 hours. Minimum and maximum SBPs were recorded each hour.

Neurologic status was assessed with the NIH Stroke Scale (NIHSS) score at baseline by a qualified study investigator. The trial mandated a head CT at 24 (± 8) hours after initiation of treatment. CT images underwent post hoc computerized volumetric analysis by central neuroimaging specialists who were blinded to the treatment assignment, clinical data, adverse events, and CT results from different time points. Postdischarge follow-up included telephone contact at 1 month to collect data on mRS scores, adverse events, and death and an in-person clinical evaluation at 90 days to perform physical and neurologic examinations and to assess the mRS score by a qualified investigator who did not participate in the randomization, treatment, or in-hospital clinical management of the study participants.

Study Outcomes

The outcome measures for the present exploratory analyses were (1) the proportion of patients with poor functional outcomes corresponding to an mRS score of 4 to 6 at 90 days; (2) death within 90 days; (3) hematoma expansion, defined as

Table 1 Demographic and Clinical Characteristics of Patients by Cohort

	From Asia (n = 537)	Outside of Asia (n = 463)	p Value	From Asia		Outside of Asia	
				Intensive (n = 264)	Standard (n = 273)	Intensive (n = 236)	Standard (n = 227)
Women	179 (33.3)	201 (43.4)	0.0011	95 (36.0)	84 (30.8)	101 (42.8)	100 (44.1)
Age, y	61.2 ± 13.0	62.9 ± 13.1	0.0375	61.5 ± 13.4	60.9 ± 12.6	62.6 ± 12.8	63.2 ± 13.4
History of stroke/TIA, n (%)	66 (12.3)	98 (21.4)	0.0001	31 (11.7)	35 (12.9)	49 (21.1)	49 (21.7)
Hypertension, n (%)	418 (80.1)	375 (83.2)	0.2175	214 (82.6)	204 (77.6)	197 (86.4)	178 (79.8)
Dyslipidemia, n (%)	98 (19.2)	143 (33.3)	<0.0001	48 (19.1)	50 (19.3)	74 (34.6)	69 (32.1)
Diabetes mellitus, n (%)	73 (13.7)	113 (24.7)	<0.0001	44 (16.8)	29 (10.7) ^a	54 (23.3)	59 (26.2)
Current smoking, n (%)	175 (32.6)	89 (19.2)	<0.0001	78 (29.6)	97 (35.5)	48 (20.3)	41 (18.1)
Glasgow Coma Scale score, n (%)	0.3898						
3–11	84 (15.6)	63 (13.6)		42 (15.9)	42 (15.4)	31 (13.1)	32 (14.1)
12–14	149 (27.8)	145 (31.3)		71 (26.9)	78 (28.6)	81 (34.3)	64 (28.2)
15	304 (56.6)	255 (55.1)		151 (57.2)	153 (56.0)	124 (52.5)	131 (57.7)
NIHSS score, n (%)	10 (6–15)	12 (6–17)	0.0204	10 (6–15)	10 (7–14.5)	12 (6–17)	11 (6–17)
Baseline SBP, mm Hg	199.9 ± 24.5	201.3 ± 29.5	0.4120	200.6 ± 24.8	199.3 ± 24.3	199.4 ± 29.4	203.3 ± 29.6
Hematoma volume, mL	10.1 (5.4–18.1)	10.3 (4.6–19.5)	0.9928	9.8 (5.3–17.6)	10.3 (5.7–18.5)	10.8 (4.6–19.6)	10.2 (4.5–19.5)
Hematoma location, n (%)	<0.0001						
Basal ganglia	300 (56.4)	178 (45.1)		144 (55.0)	156 (57.8)	111 (47.4)	96 (42.7)
Thalamus	195 (36.6)	207 (38.8)		102 (38.9)	93 (34.4)	91 (38.9)	87 (38.7)
Lobe	37 (7.0)	74 (16.1)		16 (6.1)	21 (7.8)	32 (13.7)	42 (18.7)
Intraventricular hemorrhage, n (%)	114 (21.4)	144 (31.4)	0.0004	46 (17.6)	68 (25.2) ^a	75 (32.1)	69 (30.7)
Onset-to-randomization, min	170 (125–220)	203 (154–240)	<0.0001	168.5 (125–216)	172 (125–225)	202 (147.5–242)	204 (159–240)

Abbreviations: NIHSS = NIH Stroke Scale; SBP = systolic blood pressure.

For categorical variables, numbers (percents) are presented with χ^2 *p* value. For continuous variables, mean ± SD (for normally distributed variables) or median (interquartile range) (for nonnormally distributed variables) values are presented with Wilcoxon rank *p* values. Six patients are missing data for previous stroke/TIA, 27 for hypertension, 60 for dyslipidemia, 9 for diabetes mellitus, 5 for NIHSS score, 1 for baseline SBP, and 9 for items on CT (central reading): hematoma volume, hematoma location, and intraventricular hemorrhage.

^a *p* < 0.05 vs intensive.

an increase in volume >6 cm³ on the 24-hour CT compared with the baseline CT¹¹; and (4) renal and cardiac adverse events the grade 2 to 5 of the Common Terminology Criteria for Adverse Events version 4.03 (ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm; grade 1 [mild]–grade 5 [fatal]) within 7 days. All adverse events were judged by the investigators and recorded on the case report form on the study website. Independent reviews of all severe events were conducted by the physicians in the Independent Oversight Committee, blinded to clinical outcomes. Definitions of events were identical to the previous substudy of acute SBP levels achieved after ICH.¹¹ Patients who underwent surgical procedures before the 24-hour CT were excluded from the analysis of hematoma expansion.

Statistical Analysis

A total of 1,000 patients were randomized in ATACH-2. All patients recruited in East Asia (Japan, China, Taiwan, and South Korea) were included in the Asian group, and all patients recruited outside of Asia (United States and Germany) were included in the non-Asian group, regardless of Asian or non-Asian race. Analysis of each outcome was performed under the intention-to-treat principle, including all patients randomized to either treatment group. In addition, a secondary analysis on racial differences was performed with 980 patients who self-identified as White, Black, or Asian race in accordance with the NIH guidelines for reporting race (grants.nih.gov/grants/guide/notice-files/NOT-OD-01-053.html).

Figure 1 Mean Hourly Minimum Systolic Blood Pressure During First 24 Hours After Randomization by Cohort 0 (hour), Just Before Randomization

Demographic and baseline clinical characteristics and outcomes were compared between patients from Asia and those outside of Asia (or among Asian, White, and Black participants) using χ^2 tests for categorical variables and Wilcoxon rank tests for continuous variables. Interaction effects between treatment and cohort were assessed using the cohort, treatment group, and the treatment-by-cohort interaction term as covariates and further adjusted for known predictors for clinical outcomes after ICH that were chosen in our previous substudy of ATACH-2,⁸ including sex, age, baseline NIHSS score, baseline hematoma volume, hematoma location (lobar hematoma), intraventricular hemorrhage, and time from symptom onset to randomization. Quartile categories were used for these continuous factors.

The PROC GENMOD procedure of the latest version of SAS software and JMP version 14 software (SAS Institute, Cary, NC) were used to obtain test statistics and results. Values of $p < 0.15$ were considered significant for assessment of the treatment-by-cohort interaction. In the other comparisons, values of $p < 0.05$ were considered significant because the analyses were exploratory rather than an attempt to definitively establish the existence of racial differences in the effect of intensive SBP reduction after ICH. Therefore, caution in interpretation of any significant findings is advised.

Data Availability

The whole dataset of ATACH-2 is currently open to the public and is available on request to the National Institute of Neurologic Disorders and Stroke.

Results

Comparison Between Patients Recruited in and Outside of Asia

Of a total of 1,000 patients studied (mean $\pm$ SD age, 62.0 ± 13.1 years, 380 women), 537 were recruited from Asia (288 from Japan, 137 from China, 95 from Taiwan, and 17 from South Korea), and all were of Asian race. The remaining 463 were recruited in the United States (422) and Germany (41), with 62% (287) White, 28% (131) Black, 5% (25) Asian, and 4% (20) other races. Table 1 shows the demographic and clinical characteristics compared between the patients from Asian and non-Asian regions. Of clinical significance were higher proportions of risk factors in the non-Asian cohort (history of stroke or TIA, dyslipidemia, diabetes mellitus, lobar hematoma, and intraventricular hemorrhage), but current smoking was more common in the Asian cohort. Onset-to-randomization time was 33 minutes longer in the non-Asian cohort.

On average, the Asian and non-Asian cohorts had similar profiles of SBP levels during the initial 24 hours after randomization (figure 1). The average mean hourly minimum SBPs during 24 hours were nearly identical (132.8 ± 13.9 mm Hg in Asian and 133.0 ± 13.5 mm Hg in non-Asian participants).

Figure 2 shows mRS scores at 90 days. The proportion of poor functional outcomes corresponding to an mRS score of 4 to 6 was 32.0% (170 of 532) in the Asian cohort and 45.9% (197 of 429) in the non-Asian cohort ($p < 0.0001$). Mortality, corresponding to an mRS score of 6, was 1.9% (10 of 532) in Asian and 13.3% (57 of 429) in non-Asian participants ($p <$

Figure 2 Modified Rankin Scale Score at 90 Days by Cohort

0.0001). After multivariable adjustment, the rates of both poor functional outcome (RR 0.86, 95% CI 0.74–0.99) and mortality (RR 0.19, 95% CI 0.10–0.38) were lower in Asian participants. There was no significant treatment-by-cohort interaction of poor functional outcome ($p = 0.821$) or death ($p = 0.557$, figure 3), although Asian participants showed relatively lower risk for death (RR 0.66) than non-Asian participants (RR 1.01) by intensive SBP lowering.

Early hematoma expansion was not assessed for 71 patients; baseline CT data were not available in 9; follow-up CT data were not available in 15; and follow-up CT data were affected by emergent surgery in 47. A total of 170 of the remaining 929 patients (18.3%) showed hematoma expansion. Overall, hematoma expansion was identified in 17.2% (88 of 513) of patients from Asia and 19.7% (82 of 416) of those outside of Asia ($p = 0.3168$). There was no significant treatment-by-cohort interaction of expansion ($p = 0.226$, figure 3), while hematoma expansion was less common in the intensive treatment group than in the standard treatment group after multivariable adjustment only in Asian participants (RR 0.56, 95% CI 0.38–0.83).

Cardiorenal adverse events (moderate, severe, life-threatening, or fatal) within 7 days were identified in 3.9% (21 of 537) of patients from Asia and 11.2% (52 of 463) of those outside of Asia ($p < 0.0001$). After multivariable adjustment, the rate of adverse events (RR 0.45, 95% CI 0.27–0.75) was lower in Asian participants. Details of the adverse events are documented in table 2. There was no significant treatment-by-cohort interaction of expansion ($p = 0.187$, figure 3); the rate of patients with adverse events was higher in the intensive treatment group than in the standard treatment group in both Asian (RR 3.53,

95% CI 1.29–9.64) and non-Asian participants (RR 1.71, 95% CI 1.00–2.93) after multivariable adjustment.

Comparison Among Self-Identified Racial Categories (Asian, White, and Black Participants)

Table 3 shows demographic and clinical characteristics of patients among Asian (562 patients), White (287), and Black (131) participants. Unique characteristics of Black especially compared to White participants included lower mean age, higher frequency of hypertension, and higher level of baseline SBP. The 3 groups had similar profiles of mean hourly minimum SBP during the initial 24 hours after randomization, with average SBP of 131.8 ± 13.5 mm Hg in White participants and 135.1 ± 13.6 mm Hg in Black participants ($p = 0.0502$ among 3 races).

Poor functional outcome was identified in 45.8% of White and 44.5% of Black participants ($p < 0.0001$ among 3 races [the same applies to the following], figure 2); mortality in 16.0% and 7.7%, respectively ($p < 0.0001$); hematoma expansion in 20.9% and 16.4%, respectively ($p = 0.3918$); and cardiorenal adverse events in 11.9% and 8.4%, respectively ($p = 0.0003$). After multivariable adjustment, the rate of poor functional outcome (RR 0.89, 95% CI 0.76–1.04 vs White participants; and RR 0.81, 95% CI 0.65–1.01 vs Black participants) tended to be lower and mortality (RR 0.18, 95% CI 0.09–0.33; and RR 0.27, 95% CI 0.11–0.65, respectively) was lower in Asian participants than the other 2 races. Cardiorenal adverse events were lower in Asian than White (RR 0.48, 95% CI 0.29–0.80) participants.

The treatment-by-cohort interaction was not significant for any outcomes (table 4). Hematoma expansion was less common

Figure 3 Forest Plot for Outcomes Comparing Asian and Non-Asian Cohorts

Adjusted by sex, age (quartile), baseline NIH Stroke Scale score (quartile), hematoma volume (quartile), lobar hematoma, and onset-to-randomization time (quartile). ^aThirty-nine patients with unavailable data on modified Rankin Scale score are excluded. ^bSeventy-one patients with unavailable data on follow-up CT are excluded.

(RR 0.57, 95% CI 0.39–0.83) and cardiorenal adverse events were more common (RR 2.75, 95% CI 1.15–6.56) in the intensive treatment group than in the standard treatment group after multivariable adjustment only in Asian participants.

Discussion

In the present analysis of patients from Asia and outside of Asia of the ATACH-2 trial data, the aim was to determine the association between geographic locations and clinical (90-day mRS score), imaging (hematoma expansion within 24 hours), and safety (cardiorenal adverse events within 7 days) outcomes in patients with acute ICH. One of the major findings was the large differences in ICH characteristics between the patients from Asian (to be precise, East Asian) and non-Asian regions. In particular, hematomas in the basal ganglia were more common and intraventricular hemorrhage was less common in the Asian cohort than in the non-Asian cohort. Second, the Asian cohort overall had better outcomes in terms of lower rates of poor functional outcome (32.0% vs 45.9%, absolute difference 13.9 percentage points) and death (1.9% vs 13.3%, absolute difference 11.4 percentage points) and lower incidence of cardiorenal adverse events (3.9% vs 11.2%, absolute difference 7.3

percentage points) than the non-Asian cohort. Third, intensive SBP lowering did not show significant treatment-by-cohort interactions on clinical outcomes, hematoma expansion, and cardiorenal adverse events, although the direction of the effect of intensive SBP-lowering treatment was positive in the Asian cohort with respect to death. Fourth, hematoma expansion was significantly attenuated by intensive SBP lowering only in the Asian cohort. Fifth, cardiorenal adverse events were significantly increased by intensive SBP lowering in both Asian and non-Asian cohorts. These results were similar when the 3 races by self-identification, Asian, White, and Black, were compared.

A reason for the neutral results of the ATACH-2 trial was that intensive SBP lowering did not sufficiently reduce hematoma expansion, partly because the majority of participants had relatively mild ICH, with a Glasgow Coma Scale score of 15 and median hematoma volume of 10 mL.⁷ A meta-analysis of 5 randomized controlled trials, including INTERACT2 and ATACH-2, with a total of 4,360 patients reported that intensive BP lowering was associated with a nonsignificant trend for a lower risk of death or disability at 3 months and for a lower risk of hematoma expansion.¹² A pooled analyses of INTERACT2 and ATACH-2 indicated a continuous

Table 2 Cardiorenal Adverse Events Within 7 Days

	From Asia, Intensive Treatment, n	From Asia, Standard Treatment, n	Outside of Asia, Intensive Treatment, n	Outside of Asia, Standard Treatment, n
Renal failure	7	0	6	3
Urinary retention	0	1	0	1
Increased creatinine level	0	0	1	0
Other renal adverse events	0	0	4	1
Atrial fibrillation	2	0	2	2
Hypotension	0	0	4	2
Hypertension	0	0	2	2
Tachycardia	1	1	1	1
Bradycardia	0	0	1	1
Supraventricular tachycardia	0	0	1	0
Ventricular extrasystoles	0	0	0	1
Cardiac arrest	0	1	0	2
Cardiac failure	3	1	0	0
Cardiac collapse	1	0	1	0
Myocardial infarction	0	0	1	1
Chest pain	0	0	2	0
Increased troponin level	0	0	1	1
Other cardiovascular adverse events	2	1	5	0
Total	16	5	32	18

Events with grade 2 to 5 of the Common Terminology Criteria for Adverse Events version 4.03 are listed. Most severe events in each patient are assessed.

association between the level of achieved SBP in the initial 24 hours and the distribution of mRS scores at 90 days.¹³ There were several differences in study protocols such as time allowed from symptom onset to randomization and allowable antihypertensive drug, and in therapeutic results, including the target SBP levels and the time frame to achieve those levels, between INTERACT2 and ATACH-2.^{6,7} In addition, there was a difference in the regional distribution of participants; 68% were from China in INTERACT2 and 56% were from 4 countries of East Asia in ATACH-2.

The predominance of intracranial arteriopathy and arteriolopathy is a unique feature of stroke in Asia.¹⁴ As a good example, ICH is 2 to 4 times more common in Asian than in White individuals.^{15,16} Hereditary susceptibility to intracranial vasculopathy,¹⁴ high sodium intake,¹⁷ high sensitivity to warfarin,¹⁸ and other factors cause a high incidence of ICH in Asian individuals. Asian participants had smaller hematoma size at baseline and were less likely to die and had better quality of life than White participants according to the Virtual International Stroke Trials Archive and Efficacy of Nitric Oxide in Stroke Trial involving 1,011 patients.¹⁹

Another meta-analysis reported lower mortality after ICH in Japan than other countries,¹⁶ presumably due in part to the tendency of maintaining intensive therapy even for terminal patients.

The ATACH-2 trial data present a valuable opportunity to assess baseline characteristics and outcomes of patients with ICH from Asia compared to those outside of Asia because the trial involved 1,000 participants with nearly equal proportions of Asian and non-Asian cohorts. In an analysis limited to patients receiving standard SBP-lowering treatment, poor functional outcome at 90 days was less common (32.8% vs 43.9%), as was death (2.2% vs 13.2%), in Asian than non-Asian participants, although the initial NIHSS score and hematoma volume were almost identical. Thus, patients from Asia seem to recover relatively better from ICH than those outside of Asia with the same patient selection criteria for patients independently of intensive SBP lowering.

Hematoma expansion during the initial hours is an established risk factor for poor outcome after ICH.^{20,21} In the ATACH-2 cohort, hematoma expansion was significantly associated with

Table 3 Demographic and Clinical Characteristics of Patients by Self-Identified Racial Categories

	Asian Participants (n = 562)	White Participants (n = 287)	Black Participants (n = 131)	p Value
Women, n (%)	189 (33.6)	130 (45.3)	56 (42.7)	0.002
Age, y	61.0 ± 13.1	65.6 ± 13.5	57.6 ± 10.3	<0.001
History of stroke/TIA, n (%)	70 (12.5)	57 (20.1)	32 (24.6)	<0.001
Hypertension, n (%)	439 (80.4)	219 (78.8)	119 (92.2)	0.003
Dyslipidemia, n (%)	106 (19.8)	95 (35.6)	35 (29.7)	<0.001
Diabetes mellitus, n (%)	80 (14.4)	62 (22.1)	39 (30.5)	<0.001
Current smoking, n (%)	179 (31.9)	42 (14.6)	34 (26.0)	<0.001
Glasgow Coma Scale score, n (%)				0.082
3–11	89 (15.8)	41 (14.3)	10 (7.6)	
12–14	154 (27.4)	94 (32.8)	44 (33.6)	
15	319 (56.8)	152 (53.0)	77 (58.8)	
NIHSS score	10 (6–15)	12 (6.5–17)	11 (6–18)	0.1426
Baseline SBP, mm Hg	199.7 ± 24.5	199.7 ± 29.4	206.6 ± 30.6	0.0262
Hematoma volume, mL	10.1 (5.4–18.1)	10.4 (5.0–19.6)	9.6 (4.1–18.4)	0.6901
Hematoma location, n (%)				<0.0001
Basal ganglia	310 (55.7)	126 (44.2)	63 (48.8)	
Thalamus	208 (37.3)	112 (39.3)	45 (34.9)	
Lobe	39 (7.0)	47 (16.5)	21 (16.3)	
Intraventricular hemorrhage, n (%)	122 (21.9)	89 (31.2)	42 (32.6)	0.0028
Onset-to-randomization, min	170.5 (128–221)	201 (146–240)	204 (159–265)	<0.0001

Abbreviations: NIHSS = NIH Stroke Scale; SBP = systolic blood pressure.

For categorical variables, numbers (percent) are presented with χ^2 p value. For continuous variables, mean ± SD (for normally distributed variables) or median (interquartile range) (for nonnormally distributed variables) values are presented with Wilcoxon rank p values.

poor functional outcome; 65.9% with expansion and 29.5% without expansion had poor outcomes. The possibly positive effect in INTERACT2 and the neutral effect in ATACH-2 on good clinical outcomes by intensive SBP lowering are due in part to weak protection against hematoma expansion by intensive treatment.^{6,7} In contrast, hematoma expansion was attenuated by intensive treatment in the Asian cohort of ATACH-2, showing a decrease in expansion by 9% absolutely and by 48% relative to patients receiving standard SBP lowering, although the treatment-by-cohort interaction was not significant. Black participants also showed an absolute decrease in expansion by 8% after intensive treatment, without a statistically significant difference presumably due to the small number of patients.

Median onset-to-randomization time was 33.5 minutes shorter in the Asian cohort than non-Asian cohort. A shorter time delay appears to be essential for acute ICH therapy. The rate of hematoma expansion is the highest in the initial 3 hours after symptom onset.^{11,20,22} The initial inclusion criterion of ATACH2 was not within 4.5 hours but within 3 hours of symptom onset¹⁰; 56.6% of Asian and 39.0% of non-Asian

participants met the older criterion. Time from randomization (or imaging) to reach the target SBP level was inversely associated with hematoma expansion in INTERACT2 and our multicenter, observational, Stroke Acute Management With Urgent Risk-Factor Assessment and Improvement (SAMURAI)-ICH study.^{23,24} In addition, another exploratory analysis of the ATACH-2 reported that intensive SBP lowering was associated with a decreased risk for expansion of basal ganglionic hematoma but not of thalamic hematoma or lobar hematoma.²⁵ ICH at the basal ganglia has mostly a hypertensive etiology. Severe hypertensive vasculopathy would predispose a patient to additional rupture of small vessels triggered by a BP surge, and intensive SBP lowering would prevent them from rupture and attenuate hematoma expansion. Patients from Asia had 10% more ICHs in the basal ganglia and may have received a clearer protective effect from hematoma expansion than non-Asian patients.

Cardiorenal adverse events were significantly associated with poor functional outcome in the ATACH-2 trial cohort⁸; 62.5% with events and 36.2% without events had poor

Table 4 Comparison of Outcomes Among 3 Self-Identified Racial Categories

	No.	Intensive, %	Standard, %	RR (95% CI)	<i>p</i> for Interaction (vs Asian)
Poor functional outcome^a					
Asian participants	555	31.3	33.9	1.00 (0.81–1.22)	—
White participants	269	47.8	43.7	1.02 (0.81–1.27)	0.946
Black participants	117	48.4	39.6	1.11 (0.76–1.62)	0.566
Death^a					
Asian participants	555	1.5	2.5	0.59 (0.17–2.03)	—
White participants	269	14.9	17.0	0.92 (0.49–1.75)	0.581
Black participants	117	9.4	5.7	1.32 (0.29–6.07)	0.503
Hematoma expansion^b					
Asian participants	537	12.8	21.8	0.57 (0.39–0.83)	—
White participants	258	19.7	22.1	0.97 (0.63–1.49)	0.097
Black participants	117	12.5	20.8	0.52 (0.23–1.16)	0.684
Cardiorenal adverse event					
Asian participants	562	6.5	2.5	2.75 (1.15–6.56)	—
White participants	287	14.8	9.0	1.57 (0.82–3.01)	0.280
Black participants	131	12.3	3.5	3.49 (0.96–12.8)	0.907

Abbreviations: CI = confidence interval; RR = relative risk.

Adjusted by sex, age (quartile), baseline NIH Stroke Scale score (quartile), hematoma volume (quartile), lobar hematoma, intraventricular hemorrhage, and onset-to-randomization time (quartile).

^a Thirty-nine patients with unavailable data on modified Rankin Scale score are excluded.

^b Sixty-eight patients with unavailable data on follow-up CT are excluded.

outcomes ($p < 0.0001$). The observed excess cardiorenal adverse events in intensive SBP lowering for patients with acute ICH were more common in both the Asian and non-Asian cohorts. Intensive SBP lowering is known to cause acute kidney injury in patients with acute ICH.²⁶ Thus, any beneficial effects of intensive SBP lowering on clinical outcomes by suppressing hematoma expansion may be offset by the adverse events. In addition, cardiorenal adverse events were much more common in the non-Asian than Asian cohort.

Although the patients recruited from 4 East Asian countries were regarded as the Asian cohort in the present study, Asia includes >4 dozen countries and an extremely wide variety of physical phenotypes, socioeconomic political boundaries, and cultural practices. Thus, the present results would not be generalizable to persons under the broad social category of Asian. Similarly, patients recruited only in United States and Germany were not representative of all non-Asian people. Inclusion of 25 patients from United States or Germany of Asian ancestry would strengthen or weaken the difference in the results between the Asian and non-Asian cohorts. A wide variety of factors other than differences in ancestry might underlie regional differences in ICH presentations, outcomes, and responses to interventions. These problems were essential limitations of the present study.

In addition, the following limitations to the present study need to be considered. First, patients with ICH with more severe symptoms were excluded, including those with huge hematoma and those with infratentorial hemorrhage. In fact, the patient sample in the study was dominated by cases of milder ICH, with 56% having a Glasgow Coma Scale score of 15 and median hematoma volume of 10 mL. Second, the numbers of patients in some subgroups, especially the Black group, were small, which might weaken statistical power. Third, data on premorbid mRS scores, which might influence mRS scores at 90 days, were not collected. Fourth, cardiorenal adverse events were reported by the non-blinded investigators, although severe events were checked by blinded physicians in the Independent Oversight Committee.

Patients from East Asia seemed to recover relatively better from ICH than those outside of Asia with the same patient selection criteria. Intensive SBP-lowering treatment showed a protective effect against hematoma growth in the Asian cohort, although the treatment did not improve the clinical outcomes at 3 months.

Study Funding

Supported by grants from the National Institute of Neurologic Disorders and Stroke (U01-NS061861 and U01-NS059041 to Dr. Palesch and U01-NS062091 to Dr. Qureshi), by a grant from

the Japan Society for the Promotion of Science (KAKENHI 17H04308 to Dr. Toyoda), and by a grant from the Japan Agency for Medical Research and Development (AMED 20lk0201094h0002 and 20lk0201109h0001 to Dr. Toyoda).

Disclosure

Dr. Toyoda reports honoraria from Daiichi-Sankyo, Bayer Yakuhin, Bristol-Meyers-Squibb (BMS), and Nippon Behringer Ingerheim. Dr. Koga reports honoraria from Bayer Yakuhin, BMS/Pfizer, Otsuka, Daiichi-Sankyo, Nippon Boehringer Ingelheim, and Takeda; scientific advisory board from Ono; and research support from Takeda, Daiichi-Sankyo, Nippon Boehringer Ingelheim, Astellas, Pfizer, and Shionogi. Dr. Ihara reports grants from Otsuka Pharmaceutical Ltd, BMS, and Shimadzu Corp. Dr. Hasegawa reports honoraria from Nippon Behringer Ingerheim. None of the other authors have any conflicts of interest to declare. Go to Neurology.org/N for full disclosures.

Publication History

Received by *Neurology* April 13, 2020. Accepted in final form September 25, 2020.

Appendix 1 Authors

Name	Location	Contribution
Kazunori Toyoda, MD, PhD	National Cerebral and Cardiovascular Center, Suita, Japan	Execution of ATACH2, design of the present substudy, wrote the first draft of the manuscript, statistical analysis, and provided tables, figures, and references
Yuko Y. Palesch, PhD	Medical University of South Carolina, Charleston	Execution of ATACH2, conception and design of ATACH2, design of the present substudy, statistical analysis
Masatoshi Koga, MD, PhD	National Cerebral and Cardiovascular Center, Suita, Japan	Execution of ATACH2 (major role in the acquisition of data), design of the present substudy, revised the manuscript for intellectual content
Lydia Foster, MS	Medical University of South Carolina, Charleston	Execution of ATACH2, statistical analysis, revised the manuscript for intellectual content
Haruko Yamamoto, MD, PhD	National Cerebral and Cardiovascular Center, Suita, Japan	Execution of ATACH2, design of the present substudy, revised the manuscript for intellectual content
Sohei Yoshimura, MD, PhD	National Cerebral and Cardiovascular Center, Suita, Japan	Execution of ATACH2, revised the manuscript for intellectual content
Masafumi Ihara, MD, PhD	National Cerebral and Cardiovascular Center, Suita, Japan	Execution of ATACH2, revised the manuscript for intellectual content
Mayumi Fukuda-Doi, MD, PhD	National Cerebral and Cardiovascular Center, Suita, Japan	Execution of ATACH2, revised the manuscript for intellectual content

Appendix 1 (continued)

Name	Location	Contribution
Shuhei Okazaki, MD, PhD	National Cerebral and Cardiovascular Center, Suita, Japan	Execution of ATACH2, revised the manuscript for intellectual content
Kanta Tanaka, MD	National Cerebral and Cardiovascular Center, Suita, Japan	Execution of ATACH2, revised the manuscript for intellectual content
Kaori Miwa, MD, PhD	National Cerebral and Cardiovascular Center, Suita, Japan	Execution of ATACH2, revised the manuscript for intellectual content
Yasuhiro Hasegawa, MD, PhD	St. Marianna University School of Medicine, Kawasaki, Japan	Execution of ATACH2, revised the manuscript for intellectual content
Yoshiaki Shiokawa, MD, PhD	Kyorin University School of Medicine, Mitaka, Japan	Execution of ATACH2, revised the manuscript for intellectual content
Toru Iwama, MD, PhD	Gifu University Graduate School of Medicine, Japan	Execution of ATACH2, revised the manuscript for intellectual content
Kenji Kamiyama, MD, PhD	Nakamura Memorial Hospital, Sapporo, Japan	Execution of ATACH2, revised the manuscript for intellectual content
Haruhiko Hoshino, MD, PhD	Tokyo Saiseikai Central Hospital, Japan	Execution of ATACH2, revised the manuscript for intellectual content
Thorsten Steiner, MD, PhD	Klinikum Frankfurt Höchst, Germany	Execution of ATACH2 (major role in the acquisition of data), revised the manuscript for intellectual content
Byung-Woo Yoon, MD, PhD	Seoul National University Hospital, South Korea	Execution of ATACH2 (major role in the acquisition of data), revised the manuscript for intellectual content
Yongjun Wang, MD, PhD	Beijing Tiantan Hospital, China	Execution of ATACH2 (major role in the acquisition of data), revised the manuscript for intellectual content
Chung Y. Hsu, MD, PhD	China Medical University, Taichung, Taiwan	Execution of ATACH2 (major role in the acquisition of data), revised the manuscript for intellectual content
Adnan I. Qureshi, MD, PhD	University of Minnesota, Minneapolis	Execution of ATACH2, conception and design of ATACH2, revised the manuscript for intellectual content

Appendix 2 ATACH-2 Trial Investigators

Name	Location	Role	Contribution
Kazuyuki Nagatsuka, MD	National Cerebral and Cardiovascular Center, Suita, Japan	Site investigator	Acquisition of data (79 participants)
Yongjun Wang, MD	Beijing Tiantan Hospital, China	Site investigator	Acquisition of data (72 participants)
Nobuyuki Sakai, MD	Kobe City Medical Center General Hospital, Japan	Site investigator	Acquisition of data (53 participants)

Continued

Appendix 2 (continued)

Name	Location	Role	Contribution
Takayuki Hara, MD	Toranomon Hospital, Tokyo, Japan	Site investigator	Acquisition of data (38 participants)
Zhimin Wang, MD	The First People's Hospital of Taizhou, China	Site investigator	Acquisition of data (37 participants)
Jiann-Shing Jeng, MD	National Taiwan University Hospital, Taipei	Site investigator	Acquisition of data (36 participants)
Sachin Agarwal, MD	Columbia University, New York City, NY	Site investigator	Acquisition of data (27 participants)
M. Fareed K Suri, MD	St. Cloud Hospital, MN	Site investigator	Acquisition of data (26 participants)
Qaisar A. Shah, MD	Abington Memorial Hospital, PA	Site investigator	Acquisition of data (23 participants)
Jawad F. Kirmani, MD	New Jersey Neuroscience Institute, JFK Medical Center, Edison	Site investigator	Acquisition of data (18 participants)
Ching-Huang Lin, MD	Kaohsiung Veterans General Hospital, Taiwan	Site investigator	Acquisition of data (16 participants)
Jose I. Suarez, MD	Baylor College of Medicine, Houston, TX	Site investigator	Acquisition of data (16 participants)
Pramod Sethi, MD	Guilford Neurologic Associates, Greensboro, NC	Site investigator	Acquisition of data (16 participants)
Yoshiaki Shiokawa, MD	Kyorin University, Mitaka, Japan	Site investigator	Acquisition of data (16 participants)
Yasuhiro Hasegawa, MD	St. Marianna University Hospital, Kawasaki, Japan	Site investigator	Acquisition of data (16 participants)
Chun-Lin Liu, MD	China Medical University Hospital, Taichung, Taiwan	Site investigator	Acquisition of data (16 participants)
Thomas Bergman, MD	Hennepin County Medical Center, Minneapolis, MN	Site investigator	Acquisition of data (14 participants)
Toru Iwama, MD	Gifu University Hospital, Japan	Site investigator	Acquisition of data (14 participants)
Julian Boesel, MD	University Hospital Heidelberg, Germany	Site investigator	Acquisition of data (14 participants)
Kenji Kamiyama, MD	Nakamura Memorial Hospital, Sapporo, Japan	Site investigator	Acquisition of data (13 participants)
Gustavo Pradilla, MD	Grady Memorial Hospital, Atlanta, GA	Site investigator	Acquisition of data (12 participants)
Katherine Palmieri, MD	Kansas University Medical Center, Kansas City	Site investigator	Acquisition of data (12 participants)

Appendix 2 (continued)

Name	Location	Role	Contribution
Chitra Venkata subramanian MD	Stanford University, CA	Site investigator	Acquisition of data (12 participants)
Haruhiko Hoshino, MD	Tokyo Saiseikai Central Hospital, Japan	Site investigator	Acquisition of data (12 participants)
Yuhua Chen, MD	Wuhan Brain Hospital, China	Site investigator	Acquisition of data (12 participants)

References

- GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 2019;18:439-458.
- Fonarow GC, Reeves MJ, Smith EE, et al. Characteristics, performance measures, and in-hospital outcomes of the first one million stroke and transient ischemic attack admissions in Get With The Guidelines-Stroke. *Circ Cardiovasc Qual Outcomes* 2010;3:291-302.
- Toyoda K, Inoue M, Koga M. Small but steady steps in stroke medicine in Japan. *J Am Heart Assoc* 2019;8:e013306.
- Toyoda K, Anderson CS, Mayer S, editors. *New Insights in Intracerebral Hemorrhage*. Basel: Karger AG, 2015.
- Toyoda K, Koga M, Sato S. What are the next breakthroughs in the management of acute intracerebral hemorrhage? *Int J Stroke* 2016;11:386-388.
- Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. *N Engl J Med* 2013;368:2355-2365.
- Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. *N Engl J Med* 2016;375:1033-1043.
- Toyoda K, Koga M, Yamamoto H, et al. Clinical outcomes depending on acute blood pressure after cerebral hemorrhage. *Ann Neurol* 2019;85:105-113.
- Fukuda-Doi M, Yamamoto H, Koga M, et al. Sex differences in blood pressure-lowering therapy and outcomes following intracerebral hemorrhage: results from ATACH-2. *Stroke* 2020;51:2282-2286.
- Qureshi AI, Palesch YY. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: design, methods, and rationale. *Neurocrit Care* 2011;15:559-576.
- Al-Shahi Salman R, Frantzias J, Lee RJ, et al. Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. *Lancet Neurol* 2018;17:885-894.
- Boulouis G, Morotti A, Goldstein JN, Charidimou A. Intensive blood pressure lowering in patients with acute intracerebral haemorrhage: clinical outcomes and haemorrhage expansion: systematic review and meta-analysis of randomised trials. *J Neurol Neurosurg Psychiatry* 2017;88:339-345.
- Moullaali TJ, Wang X, Martin RH, et al. Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data. *Lancet Neurol* 2019;18:857-864.
- Toyoda K, Koga M, Hayakawa M, Yamagami H. Acute reperfusion therapy and stroke care in Asia after successful endovascular trials. *Stroke* 2015;46:1474-1481.
- Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. *J Am Coll Cardiol* 2007;50:309-315.
- van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. *Lancet Neurol* 2010;9:167-176.
- Mozaffarian D, Fahimi S, Singh GM, et al. Global sodium consumption and death from cardiovascular causes. *N Engl J Med* 2014;371:624-634.
- Shen AY, Chen W, Yao JF, Brar SS, Wang X, Go AS. Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. *CNS Drugs* 2008;22:815-825.
- Krishnan K, Beishon L, Berge E, et al. Relationship between race and outcome in Asian, Black, and Caucasian patients with spontaneous intracerebral hemorrhage: data from the Virtual International Stroke Trials Archive and Efficacy of Nitric Oxide in Stroke trial. *Int J Stroke* 2018;13:362-373.
- Brott T, Broderick J, Kothari R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. *Stroke* 1997;28:1-5.
- Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. *Neurology* 2006;66:1175-1181.
- Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T. Enlargement of spontaneous intracerebral hemorrhage: incidence and time course. *Stroke* 1996;27:1783-1787.
- Carcel C, Wang X, Sato S, et al. Degree and timing of intensive blood pressure lowering on hematoma growth in intracerebral hemorrhage: intensive blood

- pressure reduction in Acute Cerebral Hemorrhage Trial-2 results. *Stroke* 2016;47:1651–1653.
24. Yamaguchi Y, Koga M, Sato S, et al. Early achievement of blood pressure lowering and hematoma growth in acute intracerebral hemorrhage: Stroke Acute Management With Urgent Risk-Factor Assessment and Improvement-Intracerebral Hemorrhage Study. *Cerebrovasc Dis* 2018;46:118–124.
25. Leasure AC, Qureshi AI, Murthy SB, et al. Association of intensive blood pressure reduction with risk of hematoma expansion in patients with deep intracerebral hemorrhage. *JAMA Neurol* 2019;76:949–955.
26. Burgess LG, Goyal N, Jones GM, et al. Evaluation of acute kidney injury and mortality after intensive blood pressure control in patients with intracerebral hemorrhage. *J Am Heart Assoc* 2018;7:1–11.

Neurology®

Regional Differences in the Response to Acute Blood Pressure Lowering After Cerebral Hemorrhage

Kazunori Toyoda, Yuko Y. Palesch, Masatoshi Koga, et al.

Neurology 2021;96:e740-e751 Published Online before print November 20, 2020

DOI 10.1212/WNL.0000000000011229

This information is current as of November 20, 2020

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/96/5/e740.full
References	This article cites 25 articles, 8 of which you can access for free at: http://n.neurology.org/content/96/5/e740.full#ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): Clinical trials Randomized controlled (CONSORT agreement) http://n.neurology.org/cgi/collection/clinical_trials_randomized_controlled_consort_agreement Intracerebral hemorrhage http://n.neurology.org/cgi/collection/intracerebral_hemorrhage
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.